The Enrollment Problem: How AI Is Closing the Gap Between Protocol Design and Patient Recruitment

Eighty percent of clinical trials fail to meet their enrollment targets on time. That single statistic explains more failed biotech programs — and more destroyed shareholder value — than any scientific hypothesis ever has.

The science is usually fine. The sites are often adequate. The patients exist. What fails is the operational infrastructure that connects them: the ability to identify the right sites, model enrollment dynamics before they become crises, and act on data fast enough to matter.

This is exactly where AI is generating some of its most measurable returns in biotech today.

Why Enrollment Is a Strategy Problem, Not Just an Operations Problem

Most clinical operations teams treat enrollment as an execution challenge. Get the sites open. Train the coordinators. Wait for the patients.

But enrollment is actually a prediction problem. You're trying to answer three questions under uncertainty:

1. Which sites will actually perform — and which will look good on paper but struggle to enroll?
2. At what rate will each site enroll, and how will that rate change over time?
3. If enrollment is running behind, what interventions will rescue it and when?

Traditional approaches rely on historical site performance data, investigator relationships, and intuition built from previous trials. For experienced CROs and sponsors, that intuition is valuable — but it's not scalable, and it doesn't update fast enough when reality diverges from forecast.

AI changes the input set and the update frequency.

Site Selection: From Gut Feel to Evidence

The most impactful application of AI in clinical operations isn't some futuristic technology — it's better use of existing data.

Electronic health records, claims databases, investigator performance registries, publication records, and ClinicalTrials.gov enrollment histories contain an enormous amount of signal about which sites are likely to enroll your patient population. Most of that signal is currently inaccessible or unused.

AI-powered site identification tools can:

• Cross-reference target indication demographics against EHR patient populations to identify sites with high potential patient prevalence
• Analyze a site's historical enrollment performance across similar trial designs — not just overall track record
• Flag sites with strong potential but thin histories (often community health systems that outperform academic centers once activated)
• Rank sites by predicted enrollment rate, not just predicted patient pool size

The result isn't magic — it's better prioritization. Top-enrolling site identification time compresses 30-50% compared to manual research. More importantly, the sites you ultimately select are more likely to actually perform.

Dynamic Enrollment Modeling

Static enrollment models are a fiction. You build a model in the feasibility phase, it immediately starts diverging from reality once sites activate, and you update it quarterly at best.

AI-assisted enrollment modeling changes two things:

Update frequency. Models that ingest real-time site-level enrollment data can reforecast weekly or even daily. You see a slow site developing into a rescue scenario weeks before it would appear in a monthly report.

Scenario modeling. Instead of a single forecast with error bars, you get a probability distribution across enrollment trajectories — and the ability to model specific interventions. What happens to your timeline if you open two additional sites in Germany? What if you expand eligibility criteria at the slow-enrolling sites? AI can run those scenarios in minutes rather than analyst-weeks.

The second capability is often more valuable than the first. The ability to model rescue options before committing to them changes how operations teams make decisions under timeline pressure.

Risk-Based Monitoring: Moving From Audit to Signal Detection

Monitoring is another area where AI is generating outsized returns, though for different reasons.

Traditional on-site monitoring is expensive, time-consuming, and catches problems after they've already happened. Risk-based monitoring changes the philosophy — focus resources where data quality signals are highest — but implementing it effectively requires the ability to detect those signals at scale.

AI-assisted anomaly detection:

• Identifies inconsistencies in data entry patterns that may indicate transcription errors or fabrication
• Flags sites with unusual query resolution patterns (too fast, too slow, or perfectly uniform)
• Detects protocol deviation clusters before they become systematic issues
• Correlates monitoring visit findings with site performance metrics to predict which sites are likely to generate issues

The compliance benefit is real. But the business benefit — catching data quality problems early enough to fix them without jeopardizing the dataset — is the one that shows up on the timeline.

The Compounding Effect

The teams getting the most out of AI in clinical operations aren't using these tools in isolation. The compounding effect comes from connecting them:

Better site selection → more productive sites → more accurate enrollment models → fewer rescue scenarios → cleaner data → faster CSR completion.

That chain of improvements is what converts a 10-15% enrollment rate improvement into a 3-6 month timeline compression. And for a clinical-stage biotech burning $2-5M per month, 6 months of timeline compression is not an operational metric — it's a financing event.

What This Looks Like in Practice

A Phase 2 trial in a rare neurological indication. 12-month enrollment target. Initial site list of 40 centers across the US and EU.

AI-assisted site selection analysis identifies that 8 of those 40 centers have strong patient prevalence in the indication but thin enrollment history — they've never run a trial in this exact disease area, but their EHR data suggests they're sitting on the patient population. Traditional feasibility would have ranked them lower.

Five of those 8 become top enrollers. The two sites that feasibility ranked highest — academic centers with strong brand names but diffuse patient populations — both underperform projections.

Enrollment modeling detects the divergence at week 6 and models the rescue scenarios. The sponsor opens two backup sites in the EU at week 8 instead of week 20.

The trial hits enrollment target on time.

That's not a hypothetical. That's a pattern that's repeating across the industry as AI-assisted clinical operations become the standard rather than the exception.

---

HaiPhai builds AI augmentation programs for clinical-stage biotech companies. Our clinical operations use cases cover protocol design, site selection, enrollment modeling, risk-based monitoring, and CSR acceleration. Get in touch to discuss your timeline.